Close

MHCLUSTER

Famotidine Aids in COVID-19 by Helping Limit Inflammation

Researchers have discovered just how the antacid famotidine, commonly sold as Pepcid by a Johnson & Johnson unit, was able to help alleviate COVID-19 symptoms in clinical trials. In studies in mice, they found that famotidine stimulates the vagus nerve, which controls the immune system and other involuntary body functions. […]

Read More

COVID-19 insights: Waning immunity will impact long-range forecasts

The latest takeaways from IHME: Regional updates: China continues the zero-COVID strategy and reports no increase in cases. South Africa may be reaching a peak of the BA.4/BA.5 winter surge. The United States is experiencing an increase in Omicron cases – likely due to behavioral changes, and possibly due to […]

Read More

Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021

Summary What is already known about this topic? As more persons are exposed to and infected by SARS-CoV-2, reports of patients who experience persistent symptoms or organ dysfunction after acute COVID-19 and develop post-COVID conditions have increased. What is added by this report? COVID-19 survivors have twice the risk for […]

Read More

Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019

Summary Background Human resources for health (HRH) include a range of occupations that aim to promote or improve human health. The UN Sustainable Development Goals (SDGs) and the WHO Health Workforce 2030 strategy have drawn attention to the importance of HRH for achieving policy priorities such as universal health coverage […]

Read More

Nucleocapsid Antibodies Appear to Be Long-Lasting After SARS-CoV-2 Infection

In a prospective, longitudinal study, N-antibodies peaked 90–100 days after infection and persisted for at least 500 days in most patients. The duration of antibody response after SARS-CoV-2 infection is not clearly established, although prior studies have estimated that antibodies produced after natural infection last from 3 to 6 months. […]

Read More

Omicron Breakthrough Cases Boost Protection, Studies Say

Vaccinated people who have a breakthrough case of Omicron will have better protection against COVID-19 variants than vaccinated people who receive a booster shot, two new studies show. The University of Washington, working with Vir Biotechnology of San Francisco, looked at blood samples of vaccinated people who had breakthrough cases of […]

Read More

CRC Screening: Blood Test Accuracy Compared to Colonoscopy

The first prospective study to evaluate the accuracy of a blood test for people being screened for colorectal cancer (CRC) revealed a high sensitivity and specificity. At 90% specificity, the blood assay (Guardant Health) was 100% sensitive for detecting CRC. At 95% specificity, sensitivity was 88%. The blood assay detects circulating tumor […]

Read More

1 in 8 Develop Myocarditis Post COVID-19 Hospitalisation

In the largest study of its kind to date researchers have found that 1 in 8 people hospitalised with COVID-19 subsequently developed myocarditis, with the severity of infection most closely linked to the severity of long-COVID symptoms. For the new prospective cohort study, led by the University of Glasgow in […]

Read More
Translate »